In the last trading session, 229.38 million Applied Dna Sciences Inc (NASDAQ:APDN) shares changed hands as the company’s beta touched 0.05. With the company’s per share price at $1.79 changed hands at $1.01 or 128.64% during last session, the market valuation stood at $18.44M. APDN’s last price was a discount, traded about -1609.5% off its 52-week high of $30.60. The share price had its 52-week low at $0.31, which suggests the last value was 82.68% up since then. When we look at Applied Dna Sciences Inc’s average trading volume, we note the 10-day average is 30.74 million shares, with the 3-month average coming to 2.35 million.

Analysts gave the Applied Dna Sciences Inc (APDN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended APDN as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Applied Dna Sciences Inc’s EPS for the current quarter is expected to be -0.3.

Applied Dna Sciences Inc (NASDAQ:APDN) trade information

Instantly APDN was in green as seen at the end of in last trading. With action 397.22%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -85.49%, with the 5-day performance at 397.22% in the green. However, in the 30-day time frame, Applied Dna Sciences Inc (NASDAQ:APDN) is 343.84% up. Looking at the short shares, we see there were 0.62 million shares sold at short interest cover period of 0.52 days.

The consensus price target for the stock as assigned by Wall Street analysts is 1.5, meaning bulls need a downside of -19.33% from its current market value. According to analyst projections, APDN’s forecast low is 1.5 with 1.5 as the target high. To hit the forecast high, the stock’s price needs a 16.2% surge from its current level, while the stock would need to tank 16.2% for it to hit the projected low.

Applied Dna Sciences Inc (APDN) estimates and forecasts

Data shows that the Applied Dna Sciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -86.02% over the past 6 months, a 80.59% in annual growth rate that is considerably higher than the industry average of 19.30%. Year-over-year growth is forecast to reach -66.30% down from the last financial year.

Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 1.6M. 2 analysts are of the opinion that Applied Dna Sciences Inc’s revenue for the current quarter will be 1.19M. The company’s revenue for the corresponding quarters a year ago was 780k and 891k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 105.10%. The estimates for the next quarter sales put growth at 33.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 45.52%. The 2024 estimates are for Applied Dna Sciences Inc earnings to increase by 67.53%.

APDN Dividends

Applied Dna Sciences Inc is expected to release its next quarterly earnings report in September.

Applied Dna Sciences Inc (NASDAQ:APDN)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 3.04% of Applied Dna Sciences Inc shares while 10.57% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 10.90%. There are 10.57% institutions holding the Applied Dna Sciences Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-03-31, the company held 9.4782% of the shares, roughly 1.3 million APDN shares worth $0.53 million.

AMH EQUITY LTD holds the second largest percentage of outstanding shares, with 3.9521% or 0.54 million shares worth $0.22 million as of 2024-03-31.